Clinical Trial Update: Neurokinin (NK) 1 Antagonist for Pathological Aggression for Harmful, Impulsive, and Self-/Aggressive Behaviour [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on a neurokinin-1 antagonist for pathological aggression and harmful, impulsive, and self-/aggressive behavior in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggression

Drugs mentioned

• Neurokinin (NK) 1 Antagonist (neurokinin-1 antagonist)

Snippet

Sponsor: St. Joseph's Healthcare Hamilton | Conditions: Aggression | Phase 1, Phase 2 | Status: UNKNOWN